ATE296881T1 - Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff - Google Patents

Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff

Info

Publication number
ATE296881T1
ATE296881T1 AT99911949T AT99911949T ATE296881T1 AT E296881 T1 ATE296881 T1 AT E296881T1 AT 99911949 T AT99911949 T AT 99911949T AT 99911949 T AT99911949 T AT 99911949T AT E296881 T1 ATE296881 T1 AT E296881T1
Authority
AT
Austria
Prior art keywords
vaccine
ompf
aroc
usable
reverting mutation
Prior art date
Application number
AT99911949T
Other languages
English (en)
Inventor
Steven Neville Chatfield
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of ATE296881T1 publication Critical patent/ATE296881T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
AT99911949T 1998-03-25 1999-03-25 Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff ATE296881T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Publications (1)

Publication Number Publication Date
ATE296881T1 true ATE296881T1 (de) 2005-06-15

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911949T ATE296881T1 (de) 1998-03-25 1999-03-25 Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff

Country Status (19)

Country Link
US (1) US6902906B1 (de)
EP (1) EP1066376B1 (de)
JP (1) JP4516210B2 (de)
KR (1) KR100628657B1 (de)
AT (1) ATE296881T1 (de)
AU (1) AU763683B2 (de)
CA (1) CA2323576C (de)
CZ (1) CZ301520B6 (de)
DE (1) DE69925585T2 (de)
DK (1) DK1066376T3 (de)
ES (1) ES2244182T3 (de)
GB (1) GB9806449D0 (de)
HU (1) HU225644B1 (de)
NO (1) NO327609B1 (de)
NZ (1) NZ507077A (de)
PL (1) PL196076B1 (de)
PT (1) PT1066376E (de)
WO (1) WO1999049026A1 (de)
ZA (1) ZA200004987B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
WO2002057780A1 (en) 2001-01-18 2002-07-25 Newcastle University Ventures Ltd. Biosensor with covalently attached membrane-spanning proteins
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
ES2776429T3 (es) 2012-12-07 2020-07-30 Elanco Tiergesundheit Ag Preparación de vacunas vivas
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
ATE111957T1 (de) 1990-02-06 1994-10-15 Pasteur Institut Transformiertes shigella.
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現

Also Published As

Publication number Publication date
PT1066376E (pt) 2005-10-31
JP4516210B2 (ja) 2010-08-04
WO1999049026A1 (en) 1999-09-30
AU763683B2 (en) 2003-07-31
HUP0105430A2 (hu) 2002-04-29
GB9806449D0 (en) 1998-05-27
EP1066376A1 (de) 2001-01-10
HU225644B1 (en) 2007-05-02
JP2002507414A (ja) 2002-03-12
CZ301520B6 (cs) 2010-03-31
NO20004781D0 (no) 2000-09-25
CA2323576A1 (en) 1999-09-30
EP1066376B1 (de) 2005-06-01
KR100628657B1 (ko) 2006-09-26
PL343246A1 (en) 2001-07-30
DK1066376T3 (da) 2005-10-03
CA2323576C (en) 2010-12-07
US6902906B1 (en) 2005-06-07
DE69925585D1 (de) 2005-07-07
KR20010042175A (ko) 2001-05-25
HUP0105430A3 (en) 2004-10-28
NZ507077A (en) 2002-10-25
NO327609B1 (no) 2009-08-31
PL196076B1 (pl) 2007-12-31
AU3045899A (en) 1999-10-18
ES2244182T3 (es) 2005-12-01
CZ20003470A3 (cs) 2001-07-11
NO20004781L (no) 2000-11-08
DE69925585T2 (de) 2006-07-13
ZA200004987B (en) 2001-10-31

Similar Documents

Publication Publication Date Title
ATE296881T1 (de) Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff
Merchel Piovesan Pereira et al. Benzalkonium chlorides: uses, regulatory status, and microbial resistance
Oyston et al. The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis
Kristich et al. Esp-independent biofilm formation by Enterococcus faecalis
Beenken et al. Mutation of sarA in Staphylococcus aureus limits biofilm formation
Murray et al. Regulation of Salmonella typhimurium lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a second Wzz
Claeys et al. The many lives of nontuberculous mycobacteria
Adékambi et al. Survival of environmental mycobacteria in Acanthamoeba polyphaga
Ngampasutadol et al. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection
Weissman et al. Clonal analysis reveals high rate of structural mutations in fimbrial adhesins of extraintestinal pathogenic Escherichia coli
Taylor et al. Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague
Poly et al. Genome sequence of a clinical isolate of Campylobacter jejuni from Thailand
Yu et al. Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection
EP0717777A4 (de) Salmonella impfstoffe
GB0424092D0 (en) Immunogenic bacterial vesicles with outer membrane proteins
Hilali et al. Prevalence of virulence genes and clonality in Escherichia coli strains that cause bacteremia in cancer patients
Oelschlaeger et al. The high-pathogenicity island is absent in human pathogens of Salmonella enterica subspecies I but present in isolates of subspecies III and VI
DE69322092D1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
Cusano et al. Pseudomonas fluorescens BBc6R8 type III secretion mutants no longer promote ectomycorrhizal symbiosis
Shrivastava et al. A Schiff base complex of chromium (III): an efficient inhibitor for the pathogenic and invasive potential of Shigella dysenteriae
Salaun et al. Phase variation mediated niche adaptation during prolonged experimental murine infection with Helicobacter pylori
DE60207278D1 (de) Attenuierte bakterien verwendbar als impstoffe
Wang et al. Revealing roles of S-layer protein (SlpA) in Clostridioides difficile pathogenicity by generating the first slpA gene deletion mutant
Fry et al. The first UK isolate of ‘Bordetella ansorpii’from an immunocompromised patient
Meyer et al. Virulence of a Salmonella typhimurium OmpD mutant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066376

Country of ref document: EP